LINC02318

Across TCGA pan-cancer cohorts, LINC02318 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated LINC02318 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LINC02318 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02318 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

CHOL, KIRC, and BLCA are the cancer types where LINC02318 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.168	0.812	<.001	36	view →
KIRC	DFS	Quartile	IV	0.412	0.689	.010	35	view →
BLCA	DFS	Tertile	All	0.622	0.206	.008	24	view →
PCPG	OS	Quartile	All	0.646	1.000	<.001	22	view →
MESO	OS	Tertile	All	0.380	0.580	.018	18	view →
BRCA	DFS	Quartile	II,III,IV	0.363	0.543	.005	15	view →
SKCM	OS	Tertile	II,III,IV	0.976	0.788	.002	9	view →
KICH	DFS	Quartile	All	0.724	0.935	.028	7	view →
PAAD	OS	Tertile	II,III,IV	0.698	0.401	.042	6	view →
ESCA	DFS	Tertile	II,III,IV	0.308	0.426	.024	6	view →
LAML	DFS	Quartile	All	0.261	0.472	.042	6	view →
THYM	DFS	Quartile	III,IV	0.149	0.755	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

LINC02318–CHOL (OS)

Open the CHOL breakdown →